[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100386201":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":7,"locations":20,"responsibleParty":32,"collaborators":34,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":7,"maxAge":47,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":64,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",null,[9,12],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"blood test for renal biomarkers","blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)",{"type":6,"name":13,"description":14,"armGroupLabels":7,"otherNames":7},"urine test for renal biomarkers","urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)",[16],{"name":17,"affiliation":18,"role":19},"Marc Pfister, Prof MD","University Children's Hospital Basel (UKBB), University of Basel","PRINCIPAL_INVESTIGATOR",[21],{"facility":18,"status":7,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Basel","4056","Switzerland","CH",{"type":27,"coordinates":28},"Point",[29,30],7.57327,47.55839,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[35],{"name":36,"class":37},"Stiftung für Krebskranke Kinder","UNKNOWN","100386201","study-to-evaluate-blood-and-urine-kidney-injury-markers-to-facilitate-early-detection-of-renal-adverse-drug-events-in-pediatric-cancer-patients-treated-with-nephrotoxic-chemotherapy-100386201",false,"NCT04308642","Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy","Pilot Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy (Kid-MaCare Oncology)","Kid-MaCareOnco","Inclusion Criteria:\n\n* signed informed consent by their-selves (≥ 14 years) or their legal representatives (\\\u003C 14 years or in case of lacking capacity of judgement)\n* cancer diagnosis, that indicates a nephrotoxic chemotherapy including the drugs High Dose MTX (HD-MTX), ifosfamide, cis- and carboplatin.\n\nExclusion Criteria:\n\n* critically-ill patients with inotropic and\u002For vasopressor drugs\n* signs of severe Sepsis\n* receiving other nephrotoxic drugs parallel to the chemotherapy cycle","ALL","18 Years",{"count":49,"type":50},6,"ACTUAL","OBSERVATIONAL","This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to detect and monitor tubular injury and renal function.",[54],"Kidney Impairment",[56,57,58,59,60,61,62,63],"nephrotoxic chemotherapy","pediatric cancer patients","renal adverse drug events","renal function","renal tubular injury","Uromodulin","drug related kidney injury","kidney markers","COMPLETED","2024-05-14",{"date":67,"type":50},"2024-05-16",{"date":69,"type":50},"2020-10-22",{"date":71,"type":50},"2023-12-31",{"name":5,"class":6},1]